- LOTTE Biologics has completed major construction and obtained approval for use for Plant 1 at its Songdo Bio Campus in Incheon, South Korea.
- The 120,000-liter antibody manufacturing facility will support large-scale commercial production and form part of the company’s dual-site CDMO network with its Syracuse Bio Campus in New York.
LOTTE Biologics has completed major construction and obtained approval for use for Plant 1 at its Songdo Bio Campus in Incheon, South Korea. The milestone was achieved approximately two years after construction began in 2024 and confirms completion of the facility’s physical construction, including production equipment, utilities, control systems, and supporting infrastructure.
The company said Songdo Plant 1 is a 120,000-liter antibody manufacturing facility equipped with eight 15,000-liter stainless-steel bioreactors. The facility is designed to support large-scale commercial production and incorporates technologies including higher-titer cell culture, perfusion processes, an automated warehouse, and real-time monitoring systems. LOTTE Biologics also implemented an automated Manufacturing Control System (MCS) during the design stage to support production efficiency and quality management.
The facility was developed using operational experience and manufacturing knowledge from the company’s Syracuse Bio Campus in New York. According to LOTTE Biologics, Songdo Plant 1 was designed to provide customized support for future commercial manufacturing projects while meeting global cGMP requirements.
The completion of the facility strengthens the company’s dual-site CDMO strategy linking South Korea and the United States. Under this model, the Syracuse Bio Campus will support early-stage customer projects and clinical supply, while Songdo Plant 1 will serve as a commercial-scale manufacturing base. The company said the structure is intended to support a range of customer requirements from clinical production through commercial manufacturing.
“Completing major construction and obtaining use approval for Songdo Plant 1 approximately two years after groundbreaking is the result of our employees’ capabilities, dedicated project execution, and strategic support and collaboration across the LOTTE Group.”
James Park, CEO of LOTTE Biologics
The company plans to begin full-scale commissioning and production system validation during the second half of the year as it works toward GMP manufacturing readiness and commercial operations.
